MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00129155|
Recruitment Status : Unknown
Verified October 2007 by Hospices Civils de Lyon.
Recruitment status was: Recruiting
First Posted : August 11, 2005
Last Update Posted : October 4, 2007
In this study, treosulfan is evaluated for conditioning in allogenic stem cell transplantation. The procedure and the follow-up are the same as in standard allogenic transplant.
The donor is unrelated (identical HLA). The graft is haematological peripheral blood stem cell.
The conditioning with reduced intensity is: fludarabine (from day -6 to day -2), treosulfan (from day -6 to day -4) and thymoglobuline (from day -2 to day -1).
|Condition or disease||Intervention/treatment||Phase|
|Hematological Malignancies Allogeneic Transplantation||Drug: treosulfan||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies|
|Study Start Date :||February 2005|
- Overall survival at 1 year
- Engraftment evaluation
- Acute and chronic graft-versus-host disease incidence and severity
- Response rate and survival without progression
- Evaluation of conditioning and transplant toxicity
- Chimerism evaluation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00129155
|Contact: Mauricette MICHALLET, MD||33 472 117 firstname.lastname@example.org|
|Hôpital Edouard Herriot||Recruiting|
|Lyon, France, 69437|
|Contact: Mauricette MICHALLET, MD 33 472 117 329 email@example.com|
|Principal Investigator: Mauricette Michallet, MD|
|Principal Investigator:||Mauricette MICHALLET, MD||Hospices Civils de Lyon|